161 related articles for article (PubMed ID: 33899766)
21. Proliferation indices correlate with diagnosis and metastasis in diagnostically challenging melanocytic tumors.
Al-Rohil RN; Curry JL; Torres-Cabala CA; Nagarajan P; Ivan D; Aung PP; Lyons GF; Bassett RL; Prieto VG; Tetzlaff MT
Hum Pathol; 2016 Jul; 53():73-81. PubMed ID: 27004944
[TBL] [Abstract][Full Text] [Related]
22. PRAME expression in melanocytic lesions of the conjunctiva.
Šekoranja D; Hawlina G; Pižem J
Histopathology; 2021 Dec; 79(6):989-996. PubMed ID: 34268800
[TBL] [Abstract][Full Text] [Related]
23. Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions.
Olds H; Utz S; Abrams J; Terrano D; Mehregan D
J Cutan Pathol; 2022 Jun; 49(6):510-514. PubMed ID: 35146798
[TBL] [Abstract][Full Text] [Related]
24. PRAME immunohistochemistry for melanoma diagnosis: A STARD-compliant diagnostic accuracy study.
O'Connor MK; Dai H; Fraga GR
J Cutan Pathol; 2022 Sep; 49(9):780-786. PubMed ID: 35672262
[TBL] [Abstract][Full Text] [Related]
25. PRAME immunohistochemistry is useful in the diagnosis of oral malignant melanoma.
Hovander D; Allen J; Oda D; Moshiri AS
Oral Oncol; 2022 Jan; 124():105500. PubMed ID: 34452831
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemistry for PRAME in Dermatopathology.
Lezcano C; Jungbluth AA; Busam KJ
Am J Dermatopathol; 2023 Nov; 45(11):733-747. PubMed ID: 37856737
[TBL] [Abstract][Full Text] [Related]
27. PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis.
Hrycaj SM; Szczepanski JM; Zhao L; Siddiqui J; Thomas DG; Lucas DR; Patel RM; Harms PW; Bresler SC; Chan MP
Histopathology; 2022 Dec; 81(6):818-825. PubMed ID: 36102613
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma.
Lezcano C; Pulitzer M; Moy AP; Hollmann TJ; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Apr; 44(4):503-508. PubMed ID: 31633488
[TBL] [Abstract][Full Text] [Related]
29. PRAME immunohistochemistry of spitzoid neoplasms.
Koh SS; Lau SK; Scapa JV; Cassarino DS
J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
[TBL] [Abstract][Full Text] [Related]
30. PRAME immunohistochemistry can distinguish melanocytic pseudonests of lichenoid reactions from melanoma in situ.
Roy SF; Panse G; McNiff JM
J Cutan Pathol; 2023 May; 50(5):450-454. PubMed ID: 36789669
[TBL] [Abstract][Full Text] [Related]
31. Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens.
Saad M; Cantley R; Hao W; Wang Z; Thomas D; Pantanowitz L; Jin X
Diagn Cytopathol; 2024 Jul; 52(7):362-368. PubMed ID: 38558495
[TBL] [Abstract][Full Text] [Related]
32. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
33. PRAME expression in melanocytic lesions of the nail.
Parra O; Linos K; Li Z; Yan S
J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
[TBL] [Abstract][Full Text] [Related]
34. PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna.
Gradecki SE; Valdes-Rodriguez R; Wick MR; Gru AA
Histopathology; 2021 Jun; 78(7):1000-1008. PubMed ID: 33280156
[TBL] [Abstract][Full Text] [Related]
35. Standardized Computer-Assisted Analysis of PRAME Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas.
Koch EAT; Erdmann M; Berking C; Kiesewetter F; Kramer R; Schliep S; Heppt MV
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047361
[TBL] [Abstract][Full Text] [Related]
36. PRAME expression in cutaneous melanoma does not correlate with disease-specific survival.
Parra O; Ma W; Li Z; Coffing BN; Linos K; LeBlanc RE; Momtahen S; Sriharan A; Cloutier JM; Wells WA; Yan S
J Cutan Pathol; 2023 Oct; 50(10):903-912. PubMed ID: 37430414
[TBL] [Abstract][Full Text] [Related]
37. Performance of PRAME immunohistochemistry compared with that of c-Kit, c-Myc, or cyclin D1 for the diagnosis of acral melanocytic tumors.
Jung JM; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
Pathol Int; 2023 Jan; 73(1):27-36. PubMed ID: 36468840
[TBL] [Abstract][Full Text] [Related]
38. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemistry for Preferentially Expressed Antigen in Melanoma in the Differential Diagnosis of Melanocytic Lesions of the Nail Apparatus.
Krajisnik A; Gharavi NM; Faries MB; Balzer BL; Frishberg DP; Martelli M; Shon W
Am J Dermatopathol; 2022 Jul; 44(7):488-492. PubMed ID: 35120028
[TBL] [Abstract][Full Text] [Related]
40. Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions.
Santandrea G; Valli R; Zanetti E; Ragazzi M; Pampena R; Longo C; Lai M; Piana S; Cesinaro AM
Am J Surg Pathol; 2022 May; 46(5):579-590. PubMed ID: 35275883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]